Orion Corporation Appoints Berkeley Vincent as Executive Vice President of Innovative Medicines
核心洞察
Orion Corporation has appointed Berkeley Vincent (搜索) as Executive Vice President, Innovative Medicines, effective April 8, 2026, as part of a strategic leadership restructuring.
The appointment reflects the company's organizational evolution to split the previously combined R&D and Innovative Medicines role into two dedicated positions to strengthen global commercialization focus.
Vincent brings over 20 years of pharmaceutical industry experience from Johnson & Johnson, including roles as President of J&J Canada and Global Commercial Leader for IMBRUVICA.
Orion Corporation announced the appointment of Berkeley Vincent (搜索) as Executive Vice President, Innovative Medicines and member of the Orion Executive Team, effective April 8, 2026. The appointment represents a strategic leadership restructuring designed to strengthen the Finnish pharmaceutical company's global commercialization capabilities as its innovative medicines pipeline expands.
Strategic Leadership Restructuring
The appointment is part of a significant organizational change in which Orion is splitting the previously combined role of R&D and Innovative Medicines into two dedicated positions. This restructuring reflects the continued growth and maturation of Orion's Innovative Medicines pipeline and the increasing need to strengthen focus on global commercialization readiness. Outi Vaarala (搜索) will continue in her role as Executive Vice President, R&D, and as a member of the Orion Executive Team.
Commercial Leadership Responsibilities
In his new role, Vincent will be responsible for defining and implementing global commercialization strategies for Orion's Innovative Medicines portfolio. His responsibilities include full profit and loss ownership, global launch sequencing, market access strategy, and the development of strategic partnerships, including licensing and acquisitions. He will work closely with R&D leadership to align development priorities with commercial and market needs.
Extensive Industry Experience
Vincent brings more than 20 years of international pharmaceutical industry experience from senior global, regional and country leadership roles at Johnson & Johnson. Most recently, he served as President, Johnson & Johnson Innovative Medicines Canada, with full P&L responsibility. His previous roles include Managing Director of the Nordic cluster and Global Commercial Leader for IMBRUVICA, providing him with relevant experience in both regional operations and oncology drug commercialization.
Vincent holds an MBA from DePaul University, Chicago (2002) and a BSc in Management from Trinity College Dublin (1999). He is an Irish and Swedish citizen, born in 1977, and will be based in Finland, reporting directly to Orion's President and CEO, Liisa Hurme (搜索).
Company Profile
Orion Pharma is a globally operating Nordic pharmaceutical company with over a century of operations. The company develops, manufactures and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients. Orion maintains an extensive portfolio of proprietary and generic medicines and consumer health products, with core therapy areas in pharmaceutical R&D focused on oncology and pain. The company's proprietary products are used to treat cancer (搜索), respiratory diseases (搜索) and neurological diseases (搜索). In 2025, Orion reported net sales of EUR 1,890 million and employs approximately 4,000 professionals worldwide.